% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wankhede:284763,
      author       = {D. Wankhede$^*$ and C. Bontoux and S. Grover and P. Hofman},
      title        = {{P}rognostic {R}ole of {KRAS} {G}12{C} {M}utation in
                      {N}on-{S}mall {C}ell {L}ung {C}ancer: {A} {S}ystematic
                      {R}eview and {M}eta-{A}nalysis.},
      journal      = {Diagnostics},
      volume       = {13},
      number       = {19},
      issn         = {2075-4418},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-02074},
      pages        = {3043},
      year         = {2023},
      note         = {#EA:C070#},
      abstract     = {KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS
                      point mutation in non-small cell lung cancer (NSCLC) and has
                      been proven to be a predictive biomarker for direct KRAS
                      G12C inhibitors in advanced solid cancers. We sought to
                      determine the prognostic significance of mKRAS G12C in
                      patients with NSCLC using the meta-analytic approach. A
                      protocol is registered at the International Prospective
                      Register for systematic reviews (CRD42022345868). PubMed,
                      EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were
                      searched for prospective or retrospective studies reporting
                      survival data for tumors with mKRAS G12C compared with
                      either other KRAS mutations or wild-type KRAS (KRAS-WT). The
                      hazard ratios (HRs) for overall survival (OS) or
                      Disease-free survival (DFS) of tumors were pooled according
                      to fixed or random-effects models. Sixteen studies enrolling
                      10,153 participants were included in the final analysis.
                      mKRAS G12C tumors had poor OS [HR, 1.42; $95\%$ CI,
                      1.10-1.84, p = 0.007] but similar DFS [HR 2.36, $95\%$ CI
                      0.64-8.16] compared to KRAS-WT tumors. Compared to other
                      KRAS mutations, mKRAS G12C tumors had poor DFS [HR, 1.49;
                      $95\%$ CI, 1.07-2.09, p < 0.0001] but similar OS [HR, 1.03;
                      $95\%$ CI, 0.84-1.26]. Compared to other KRAS mutations,
                      high PD-L1 expression $(>50\%)$ [OR 1.37 $95\%$ CI
                      1.11-1.70, p = 0.004] was associated with mKRAS G12C tumors.
                      mKRAS G12C is a promising prognostic factor for patients
                      with NSCLC, negatively impacting survival. Prevailing
                      significant heterogeneity and selection bias might reduce
                      the validity of these findings. Concomitant high PD-L1
                      expression in these tumors opens doors for exciting
                      therapeutic potential.},
      subtyp        = {Review Article},
      keywords     = {KRAS (Other) / KRAS G12C (Other) / NSCLC (Other) /
                      meta-analysis (Other) / non-small cell lung cancer (Other) /
                      systematic review (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37835787},
      pmc          = {pmc:PMC10572143},
      doi          = {10.3390/diagnostics13193043},
      url          = {https://inrepo02.dkfz.de/record/284763},
}